Core Insights - Edesa Biotech's CEO, Dr. Par Nijhawan, has been selected to present at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the Phase 3 results for paridiprubart in treating ARDS patients [1][3] Group 1: Presentation and Study Results - Dr. Nijhawan's presentation will focus on findings from the Phase 3 study of paridiprubart (EB05), an anti-TLR4 antibody for Acute Respiratory Distress Syndrome (ARDS), which leads to over three million ICU admissions globally each year [2] - The Phase 3 results include data from an initial 104 patients requiring invasive mechanical ventilation and expanded results from a broader 278-patient population, reinforcing the potential clinical benefits of paridiprubart [2] Group 2: Upcoming Events - The presentation by Dr. Nijhawan is scheduled for May 15, 2026, with an accompanying poster presentation by Edesa's research team at the summit [3] - Ted Steiner, MD, will present a full oral presentation of the Phase 3 results on May 20, 2026, during the ATS 2026 International Conference, focusing on the study's design and outcomes [4] Group 3: Product Overview - Paridiprubart is a new class of host-directed therapeutics designed to modulate the immune response against various health threats, including infectious diseases and other public health emergencies [5] - The drug works by inhibiting toll-like receptor 4 (TLR4), which is activated by various pathogens and is involved in chronic autoimmune diseases [5] Group 4: Company Background - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory and immune-related diseases, with a pipeline that includes therapies for both medical dermatology and respiratory conditions [6] - The company is developing EB06 for vitiligo and EB01 for allergic contact dermatitis, alongside its lead respiratory candidate, paridiprubart, which is supported by funding from the Government of Canada [6]

Core Insights - Edesa Biotech, Inc. has announced that its CEO, Dr. Par Nijhawan, will deliver the inaugural presentation at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the company's Phase 3 study results for paridiprubart, an anti-TLR4 antibody for treating Acute Respiratory Distress Syndrome (ARDS) [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, with a clinical pipeline targeting Medical Dermatology and Respiratory conditions [6] - The company is developing paridiprubart (EB05) as a treatment for ARDS, a condition that leads to over three million ICU admissions globally each year [2][6] Clinical Study Details - The Phase 3 study of paridiprubart has reported results from an initial cohort of 104 patients requiring invasive mechanical ventilation, followed by expanded results from a total of 278 patients, indicating potential clinical benefits [2] - Dr. Ted Steiner, the principal investigator of the Phase 3 study, will present comprehensive results at the ATS 2026 International Conference on May 20, 2026 [4] Presentation Significance - Dr. Nijhawan expressed that being invited to lead the innovation showcase is a validation of the strength of the Phase 3 data and the potential of paridiprubart to transform ARDS treatment, which currently has limited effective options [3] Therapeutic Mechanism - Paridiprubart represents a new class of host-directed therapeutics designed to modulate the immune response against various public health threats, including infectious diseases and other emergencies [5]

Core Viewpoint - Edesa Biotech, Inc. is advancing its Phase 2 clinical study of EB06 for moderate-to-severe nonsegmental vitiligo, with enrollment expected to begin mid-2026, following the selection of JSS Medical Research as its clinical research organization [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for immuno-inflammatory diseases, with a pipeline that includes EB06 for vitiligo and other assets for allergic contact dermatitis and respiratory conditions [7][8] Clinical Study Details - The Phase 2 study will assess the safety and efficacy of EB06 compared to placebo in adults with non-segmental vitiligo, involving intravenous infusions during the treatment period followed by a follow-up [4] - Site activations and patient recruitment for the clinical trial are anticipated to start in mid-2026, with initial sites located in Canada [2] Drug Mechanism and Background - EB06 is a monoclonal antibody targeting chemokine ligand 10 (CXCL10), which is implicated in the autoimmune response in vitiligo by promoting the trafficking of anti-melanocytic T-cells and inducing melanocyte apoptosis [5][6] - Preclinical studies have shown that EB06 can prevent and reverse depigmentation, demonstrating pharmacodynamic activity necessary to address the immune dysfunction associated with vitiligo [5] Vitiligo Overview - Vitiligo is a chronic autoimmune condition affecting 0.5% to 2% of the global population, characterized by unpredictable loss of skin pigmentation, often beginning before the age of 20 [6]

Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical programs, particularly in dermatology and respiratory diseases, while reporting a net loss for the first quarter of 2026, reflecting ongoing investments in drug development and manufacturing [1][5]. Financial Performance - Total operating expenses increased by $0.4 million to $2.3 million for the three months ended December 31, 2025, compared to $1.9 million for the same period in the previous year [4]. - Edesa reported a net loss of $2.2 million, or $0.28 per common share, for the quarter ended December 31, 2025, compared to a net loss of $1.6 million, or $0.48 per common share, for the same quarter in 2024 [5][13]. - Cash and cash equivalents at December 31, 2025, were $12.1 million, with working capital of $12.0 million [6]. Drug Development Progress - Edesa is progressing with the manufacturing of its dermatology drug candidate, EB06, for a Phase 2 study in moderate-to-severe nonsegmental vitiligo, with recruitment expected to begin midyear 2026, pending regulatory approvals [2][3]. - The company is evaluating subgroup data for additional efficacy signals in its respiratory program following positive results from a Phase 3 study of paridiprubart in patients with Acute Respiratory Distress Syndrome [2][3]. Research and Development - Research and development expenses increased by $0.1 million to $1.1 million for the three months ended December 31, 2025, primarily due to increased manufacturing-related activities for the EB06 program [7]. - General and administrative expenses rose by $0.3 million to $1.2 million for the same period, mainly due to an increase in noncash share-based compensation [7]. Upcoming Events - Edesa plans to participate in several upcoming scientific and medical conferences, including the Global Vitiligo Foundation Annual Scientific Symposium on March 26, 2026, and the American Thoracic Society 2026 International Conference from May 15-20, 2026 [8].

Core Insights - Edesa Biotech, Inc. reported financial results for the fiscal year ended September 30, 2025, highlighting advancements in its clinical programs and financial performance [1][4]. Financial Performance - Total operating expenses increased by $0.9 million to $7.9 million for the year ended September 30, 2025, compared to $7.0 million for the prior year [4]. - Edesa reported a net loss of $7.2 million, or $1.27 per common share, compared to a net loss of $6.2 million, or $1.93 per common share, for the year ended September 30, 2024 [5]. - Cash and cash equivalents at September 30, 2025, were $10.8 million, with working capital of $10.4 million [6]. Clinical Developments - The company initiated manufacturing activities for a Phase 2 study of EB06, an anti-CXCL10 monoclonal antibody, targeting moderate-to-severe nonsegmental vitiligo, with recruitment expected to begin by mid-2026 [2]. - A Phase 3 study of paridiprubart (EB05) met primary and secondary endpoints with statistical significance, and the company is exploring partnerships for its development and commercialization [2][3]. Strategic Initiatives - Edesa's CEO emphasized the company's strategy to advance both dermatology and respiratory assets, aiming to deliver transformative therapies to patients with high unmet medical needs [3]. - The CFO noted that the company strengthened its balance sheet and extended its Canadian government funding agreement to support manufacturing and development for its respiratory program [3]. Research and Development Expenses - Research and development expenses increased by $0.8 million to $3.7 million for the year ended September 30, 2025, primarily due to increased manufacturing-related activities and preparations for the Phase 2 clinical study of EB06 [7]. - General and administrative expenses rose by $0.1 million to $4.2 million, mainly due to increased noncash share-based compensation [7]. Future Outlook - Edesa plans to participate in one-on-one meetings during JP Morgan week starting January 12, 2026, to engage with potential strategic and government partners [7].

Core Viewpoint - Edesa Biotech reported stable financial results for Q3 2025, with a GAAP EPS loss of $(0.25), slightly better than the consensus estimate, while maintaining a focus on advancing its clinical assets in dermatology and respiratory diseases [1][2][3]. Financial Performance - GAAP EPS loss narrowed to $(0.25) from $(0.52) year over year, reflecting a 51.9% improvement [2][6] - Revenue remained at $0, consistent with the company's pre-commercial status [1][2] - Operating expenses were $1.9 million, unchanged from the prior year [5][2] - Net loss was $(1.7 million), remaining stable year over year [2][6] - Cash and cash equivalents stood at $12.4 million as of June 30, 2025 [1] Company Overview and Strategy - Edesa Biotech focuses on developing therapies for immune and inflammatory diseases, particularly in dermatology and respiratory conditions [3][10] - The company has realigned resources towards dermatology, prioritizing the development of EB06, an experimental anti-CXCL10 monoclonal antibody [4][10] Clinical Development - Edesa Biotech is advancing EB06 for treating moderate-to-severe nonsegmental vitiligo, with plans to submit an IND application to the FDA by the end of 2025 [7] - The EB05 program for acute respiratory distress syndrome is progressing under a government-funded clinical platform, reducing near-term R&D cash burden [7][11] - The EB01 asset for allergic contact dermatitis is Phase 3-ready but received less focus during the quarter [7] Operational Focus and Future Outlook - The company emphasized careful spending and operational efficiency, with no dividends declared during the period [8][12] - Management did not provide numerical forward guidance but highlighted ongoing preparations for EB06's manufacturing data [12][13] - Investors are encouraged to monitor clinical timelines and regulatory submissions that could impact operational costs and pipeline progress [13]

Core Viewpoint - Edesa Biotech, Inc. is advancing its drug candidate EB06 for treating moderate-to-severe nonsegmental vitiligo and has reported financial results for the three and nine months ended June 30, 2025, indicating a strategic focus on this development program [1][2][3]. Financial Performance - For the three months ended June 30, 2025, total operating expenses were $1.9 million, consistent with the same period in 2024 [5]. - The net loss for the quarter was $1.7 million, or $0.25 per common share, compared to a net loss of $1.7 million, or $0.52 per common share, for the same period in 2024 [6]. - For the nine months ended June 30, 2025, total operating expenses decreased by $0.6 million to $5.4 million compared to $6.0 million for the same period in 2024 [7]. - The net loss for the nine months was $5.0 million, or $0.95 per common share, compared to a net loss of $5.2 million, or $1.64 per common share, for the same period in 2024 [10]. Research and Development Focus - Research and development expenses for the nine months ended June 30, 2025, decreased by $0.4 million to $2.4 million, primarily due to reduced external research expenses related to EB05, offset by increased expenses for EB06 [7]. - The company is channeling operational efforts into regulatory preparation and drug manufacturing for EB06, aiming for rapid progression into clinical testing [4]. Cash Position and Working Capital - As of June 30, 2025, Edesa had cash and cash equivalents of $12.4 million and working capital of $12.1 million [11]. Upcoming Events - Edesa management is scheduled to participate in the Canaccord Genuity 45th Annual Growth Conference on August 12-13, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025 [12].

Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical-stage biopharmaceutical development, particularly focusing on its vitiligo drug candidate EB06, while reporting financial results that reflect a strategic pivot in operational activities towards this program [1][4]. Financial Overview - For the three months ended March 31, 2025, total operating expenses decreased by $0.6 million to $1.6 million compared to $2.2 million for the same period in 2024 [7] - The company reported a net loss of $1.6 million, or $0.30 per common share, for the quarter, an improvement from a net loss of $1.9 million, or $0.58 per common share, for the same quarter last year [8] - For the six months ended March 31, 2025, total operating expenses decreased by $0.6 million to $3.5 million compared to $4.1 million for the same period in 2024 [9] - The net loss for the six months was $3.2 million, or $0.74 per common share, compared to a net loss of $3.5 million, or $1.12 per common share, for the same period last year [11] Business Development - The company completed a $15 million equity financing to support the development of EB06, an anti-CXCL10 monoclonal antibody for vitiligo [2] - Edesa has initiated outreach to potential investigators and manufacturing activities to support U.S. regulatory approval for a Phase 2 study in moderate-to-severe nonsegmental vitiligo patients [2][6] - The planned Phase 2 study for EB06 is already approved in Canada, with drug manufacturing data expected to be submitted to the FDA in the second half of 2025 [6] Research and Development - Research and development expenses decreased by $0.7 million to $0.5 million for the three months ended March 31, 2025, primarily due to decreased external research expenses related to the investigational drug paridiprubart [9][16] - General and administrative expenses increased by $0.2 million to $1.2 million for the three months ended March 31, 2025, mainly due to increased salaries and related costs [9] Cash Position - As of March 31, 2025, Edesa had cash and cash equivalents of $13.9 million and working capital of $13.5 million [12]

Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases [1][3] - The company has a clinical pipeline targeting two therapeutic areas: Medical Dermatology and Respiratory [3] Medical Dermatology - Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate for treating vitiligo, an autoimmune disorder [3] - The company also has EB01 (1.0% daniluromer cream), which is Phase 3-ready for moderate-to-severe chronic Allergic Contact Dermatitis (ACD) [3] Respiratory - The most advanced respiratory drug candidate is EB05 (paridiprubart), currently evaluated in a U.S. government-funded study for Acute Respiratory Distress Syndrome [3] - EB05 has received two funding awards from the Government of Canada to support its development [3] - Edesa is preparing an investigational new drug application (IND) for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis [3] Upcoming Events - Edesa will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference on May 5-6, 2025, in Toronto [1][2] - Management is scheduled to present on May 5 at 4:00pm ET [2]